

ENSAYOS CLÍNICOS FASE I

- TUMORES SÓLIDOS

AMGEN 20140318

"A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors"

<https://clinicaltrials.gov/ct2/show/NCT02509507?term=20140318&rank=1>

AMGEN 20140299

"A phase Ib open-label study to evaluate the safety and efficacy of MPDL3280A (Atezolimumab) in combination with talimogene laherparepvec in patients with triple negative breast cancer and in patients with colorectal cancer with liver metastases unsuitable for surgical resection"

<https://clinicaltrials.gov/ct2/show/NCT03256344?term=20140299&rank=1>

CPDR001X2103

"Estudio de fase Ib, abierto y multicéntrico, para caracterizar la seguridad, tolerabilidad y farmacodinámica (PD) de PDR001 en combinación con CIM112, EGF816, Ilaris® (canakinumab) o Mekinist® (trametinib)"

<https://clinicaltrials.gov/ct2/show/NCT02900664?term=CPDR001X2103&rank=1>

BAY94-9343/15834

"Estudio de fase Ib de múltiples indicaciones con anetumab ravtansina (BAY-94-9343) en pacientes con cáncer avanzado o recurrente que expresan mesotelina". Mama, Pulmón, Cabeza y Cuello y Gástrico.

<https://clinicaltrials.gov/ct2/show/NCT03102320?term=15834&rank=1>

CLGK974X2101

"Estudio fase I, abierto, de escalada de dosis de LGK974 oral, en pacientes con enfermedades malignas dependientes de ligandos de Wnt".

<https://clinicaltrials.gov/ct2/show/NCT01351103?term=CLGK974X2101&rank=1>

CLHC165X2101

"Estudio Fase I/Ib, multicéntrico, abierto, de escalada de dosis y de expansión de dosis sobre la seguridad y tolerabilidad de LHC165 administrado por vía intratumoral en monoterapia y en combinación con PDR001 en pacientes con neoplasias malignas avanzadas"

<https://clinicaltrials.gov/ct2/show/NCT03301896?term=CLHC165X2101&rank=1>

CNZV930X2101

"Estudio de fase I/Ib, multicéntrico y abierto de NZV930 en monoterapia y en combinación con PDR001 y/o NIR178 en pacientes con tumores malignos avanzados"

<https://clinicaltrials.gov/ct2/show/NCT03549000?term=CNZV930X2101&recrs=a&phase=0&rank=1>

IOV-COM-202

"A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors"

<https://clinicaltrials.gov/ct2/show/NCT03645928?term=IOV-COM-202&rank=1>

BI 1381.2

"An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 in patients with advanced solid cancers followed by expansion cohorts at the selected dose of the combination in patients with non-small cell lung cancer and other solid tumors"

<https://clinicaltrials.gov/ct2/show/NCT03156114?term=BI+1381&rank=3>

MK-7902-005-00

"A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)"

<https://clinicaltrials.gov/ct2/show/NCT03797326?term=MK-7902-005&rank=1>

B9991032

"A phase 2 study to evaluate safety and anti-tumor activity of avelumab in combination with talazoparib in patients with brca or atm mutant tumors"

<https://clinicaltrials.gov/ct2/show/NCT03565991?term=b9991032&rank=1>

CA209-8KX

"Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy. Pulmón, Renal, Melanoma, Hcc y Colon"

<https://clinicaltrials.gov/ct2/show/NCT03656718?term=CA209-8KX&rank=1>

CVPM087A2101

"Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapy in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma".

<https://clinicaltrials.gov/ct2/show/NCT03798626?term=CVPM&rank=1>

M16-074

"A Multicenter, phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics of ABBV-368 as a single agent and combination in subjects with locally advanced or metastatic solid tumors".

Ds8201-A-U-105

<https://clinicaltrials.gov/ct2/show/NCT03523572?term=8201-a-u-105&rank=1>

"A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer"

CLXH

<https://clinicaltrials.gov/ct2/show/NCT02607813?term=CLXH254X2101&draw=2&rank=1>

"A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations"

- **SARCOMAS**

TRASTS

“Ensayo Clínico Fase I-II abierto, prospectivo y multicéntrico, que explora la combinación de trabectedina y radioterapia en pacientes con sarcoma de tejidos blandos”

<https://clinicaltrials.gov/ct2/show/NCT02275286?term=TRASTS&rank=1>

GEIS 58-OLATRASTS

“Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado”

- **PULMON**

61186372EDI1001

“A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer”

1ª/2ª/3ª LINEA EGFR/cMET ALTERADO

<https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&rank=1>

- **PULMON/CABEZA-CUELLO**

CLOVER

“Estudio de fase I, multicéntrico de inmunoterapia en combinación con quimiorradioterapia en pacientes con tumores sólidos avanzados (CLOVER- D933BC00001)”

<https://clinicaltrials.gov/ct2/show/NCT03509012?term=D933BC00001&rank=1>

- **MAMA**

GSK 201973

“Estudio de fase I/II de aumento escalonado y expansión de dosis para investigar la seguridad, farmacocinética, farmacodinamia y actividad clínica de GSK525762 en combinación con fulvestrant en pacientes con cáncer de mama con receptores estrogénicos positivos RE +”

<https://clinicaltrials.gov/ct2/show/NCT02964507?term=201973&rank=1>

GO39932

“Estudio de fase Ia/Ib, multicéntrico, abierto, de aumento escalonado de la dosis y de ampliación de la dosis para evaluar la seguridad, la farmacocinética y la actividad de GDC-9545 en monoterapia o en combinación con palbociclib y/o con un agonista de la LHRH en pacientes con cáncer de mama localmente avanzado o metastásico positivo para los receptores de estrógenos”.

<https://clinicaltrials.gov/ct2/show/NCT03332797?term=GO39932&rank=1>

CLSZ102X2101

"A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy"

<https://clinicaltrials.gov/ct2/show/NCT02734615?term=CLSZ&rank=1>

MEN1611- PRECISE

<https://clinicaltrials.gov/ct2/show/NCT03767335?term=MEN1611&rank=1>

"Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy"

- PRÓSTATA

5602192PCR2032 – KRONOS

"Estudio abierto, multicéntrico, fase 1b de JNJ-63723283, un inhibidor de la PD-1, administrado con Apalutamida en hombres con cáncer de próstata metastásico resistente a castración"

<https://clinicaltrials.gov/ct2/show/NCT03551782?term=5602192PCR2032&rank=1>

- HEPATÁTICO

H3B-6527-G000-101

"An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma"

<https://clinicaltrials.gov/ct2/show/NCT02834780?term=H3B-6527-G000-101&rank=1>

- PÁNCREAS

WO39608

"Estudio en paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con adenocarcinoma ductal pancreático metastásico (morpheus-cáncer pancreático)"

<https://clinicaltrials.gov/ct2/show/NCT03193190?term=WO39608&rank=1>

- UROTELIO/VEJIGA

WO39613

"ESTUDIO EN PARAGUAS DE FASE IB / II, ABIERTO, MULTICÉNTRICO, ALEATORIZADO, QUE EVALÚA LA EFICACIA Y LA SEGURIDAD DE LAS COMBINACIONES DE TRATAMIENTOS BASADOS EN MÚLTIPLES INMUNOTERAPIAS EN PACIENTES CON CARCINOMA UROTELIAL LOCALMENTE AVANZADO O METASTÁSICO TRAS FRACASO DE TRATAMIENTO CON QUIMIOTERAPIA CON PLATINO (MORPHEUS-Muc)"

<https://clinicaltrials.gov/ct2/show/NCT03869190?term=WO39613&rank=1>



**Hospital General Universitario
Gregorio Marañón**

 **Comunidad de Madrid**



- MELANOMA

CA209-8FC

"A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma".

<https://clinicaltrials.gov/ct2/show/NCT03980314?term=CA209-8FC&rank=1>